Medical Treatment of Female Sexual Dysfunction

Female sexual dysfunction, particularly hypoactive sexual desire disorder, has historically been undertreated due to limited therapeutic options. This review by Nappi, Tiranini, Martini, and colleagues examined the current landscape of medical treatments available for female sexual dysfunction.

The authors surveyed the available pharmacological options for treating female sexual dysfunction, evaluating their mechanisms of action, clinical evidence, efficacy, and safety profiles. The review provided a comprehensive assessment of where the field stands and which treatments show the most promise.

The review highlighted bremelanotide (PT-141) as an effective FDA-approved treatment option for hypoactive sexual desire disorder in premenopausal women. Its unique mechanism of action through melanocortin receptors in the central nervous system distinguishes it from other approaches and offers on-demand treatment flexibility.

For women experiencing hypoactive sexual desire disorder, having an FDA-approved peptide therapy represents a significant advancement in clinical care. PT-141's validation through rigorous clinical trials and regulatory approval provides both patients and prescribers with confidence in its safety and effectiveness as a treatment option.